Eithne01,
The treatment of chronic myeloid leukemia (CML) has changed significantly since the late 1990s, with the development and subsequent approval by the Food and Drug Administration of imatinib (in 2001), the first of a class of medications called tyrosine kinase inhibitors, which target the specific abnormality that causes CML.
Before that time, patients were treated with other therapy, including interferon and bone marrow transplant, and had very poor outcomes.
Are you currently on any medication like imatinib? The neutropenia can be due to your current medication. You can ask your hematologist for G-CSF injection if you have persistent neutropenia. Patients with CML are immunocompromised and can easily acquire infections. Neutropenia also puts a patient in an immunocompromised state.
For now, it is very important to prevent acquiring any infection. You should avoid crowded places and persons with ongoing infection.
Good luck.
Hi.
Chronic Myelogenous Leukemia (CML) is a blood disorder caused by an acquired genetic defect in the pleripotent stem cell. It has several phases: indolent chronic or stable phase, aggressive or advanced phase, and accelerated and blastic phase. The transition between phases may take years (on the average, 4 to 6 years from the stable phase to aggressive phase).
Average survival rates are generalizations, not applicable to a particular patient. The prognosis is relatively good. Newer techniques are being tried, including imatinib and stem cell transplantation.
All the best, and God Bless!
The fine print about the bioequivalence, shown at the bottom of this letter, is all we know about the comparison between the old and new formulations.
5. They received a call yesterday from someone asking if aspartame had been added to the new formula.
6. Pfizer thanked me for my "concerns" (God, how I hate that word), and they got an earful from me about their failure to communicate effectively with their customers.
Mark Yannone
SplendaSickness.blogspot.com
AspartameSickness.
Regarding ribavirin I agree with others; there should be letters of bioequivalence available from various manufacturers and again, no clinical difference in product efficacy.
TY for the reply. Yes I was told and am thinking that its parasitc or allergy. I went to aruba in June but that wouldn't have an affect on me now, would it?
There are a lot more factors that go into generics vs. brands (like its pharmacokinetic profile and bioequivalence (BE) and bioavailability (BA).....but it's a tad more complicated than is appropriate for this forum)
There has been a VERY long lived debate about the efficacy of generic vs brand name meds. For most people, they seem to be able to use either interchangeably with little or no difference in the effectiveness.
Therapy with corticosteroids is used for the treatment of most and additional therapy is available and dependent upon the type of HS. Newer medicines such as imatinib and mepolizumab are said to be promising. So, should your son have HS, there is reason to be optimistic regarding a positive response to currently available therapy.
You should request, of his doctor, an additional explanation for the tentative diagnosis of pre-hypertension.
Good luck.
Patients with hypereosinophilic syndrome should be tested for the presence of the FIP1L1-PDGRFA-mutatition in order to identify patients that could benefit from a treatment with a tyrosine kinase inhibitor such as Imatinib. At present, immunosuppression is still the treatment of first choice for Churg-Strauss syndrome. Novel treatment modalities for both diseases include immunomodulation with interferon alpha and biologics such as antibodies against interleukin 5.
PET CT SCAN mentioned no metabolically alive cells, As precaution I was put on Imatinib for last 4 months. LFT was normal for first 3 months, This month I have raised SGOT & SGPT LEVELS & also HBV Ag is positive ( Was Negative in test done before my Surgery).Should I continue on Imatinib or need to go for a second opinion. What is the course duration & Will this HBV ben cured.
Recommended
